Efficacy News and Research

RSS

Critical care journal editors release joint statement affirming commitment to ethical conduct of research

In response to an announcement by the German State Medical Association of Rheinland-Pfalz of their initial review of more than 100 articles by Professor Joachim Boldt, Steven L. Shafer, MD, Editor-in-Chief of Anesthesia & Analgesia, has joined with ten other anesthesiology and critical care journal editors in releasing a joint statement affirming their commitment to ethical conduct of research.

5 Feb 2011

Radical regulatory reform for life science industries needs to be a priority: Researchers

This declining trend is blamed on a failure of innovative drive in the industry, failure of the UK to support basic research, failure of venture capital to invest in early stage research, or failure of the Health Service to provide smart procurement.

5 Feb 2011

Ameritox makes significant strides to advance its industry leadership position

Ameritox, the nation's leader in pain medication monitoring, made significant strides to advance its industry leadership position by strengthening the company's commitment to physicians and patients in the past twelve months.

5 Feb 2011

Stiefel introduces BPO Acne Creamy Washes for OTC use in the U.S.

Stiefel, a GSK company, today announced the launch of the most-prescribed BPO Acne Wash formulations for over-the-counter use in the United States.

5 Feb 2011

Phase II results of VELCADE in patients with aggressive lymphoma published in Journal of Clinical Oncology

Millennium: The Takeda Oncology Company today announced that Phase II results of a clinical trial examining VELCADE (bortezomib) in patients with previously untreated aggressive lymphoma were published in the Journal of Clinical Oncology.

5 Feb 2011

Amgen, Pfizer present Enbrel new trial results against psoriasis at 69th AAD meeting in New Orleans, LA

Amgen and Pfizer Inc. today announced results from a new trial that demonstrated Enbrel significantly improved scalp involvement in adult patients with moderate to severe plaque psoriasis, compared with placebo. The data will be presented today at the 69th Annual American Academy of Dermatology meeting in New Orleans, La.

5 Feb 2011

Microsulis' Microwave Endometrial Ablation platform sold to Hologic

Microsulis Medical Limited announced this week that it has exclusively licensed to Hologic Inc all rights to its microwave technology in the gynecology and female urology fields of use.

From Hologic, Inc. 5 Feb 2011

Anacor initiates dosing in AN2728 Phase 2b trial for psoriasis

Anacor Pharmaceuticals announced today that the first patient has been dosed in a Phase 2b trial of AN2728, a topical anti-inflammatory product candidate for the treatment of psoriasis. Psoriasis is a chronic inflammatory skin disease that affects approximately 7.5 million people in the United States and over 100 million people worldwide.

4 Feb 2011

EntreMed announces publication of ENMD-2076 Phase 1 results against solid tumors in AACR journal

EntreMed, Inc., today announced the publication of key papers on the clinical and preclinical development of ENMD-2076, an Aurora A/angiogenic kinase inhibitor. The clinical data were published in the December 3, 2010 on-line issue of the American Association for Cancer Research journal, Clinical Cancer Research, and are expected to appear soon in the print version of the publication.

4 Feb 2011

Positive results from KYTHERA's ATX-101 Phase IIb study for reduction of submental fat

KYTHERA Biopharmaceuticals, Inc. today announced that it has successfully completed a third Phase II clinical study with ATX-101, a first-in-class adipolytic agent that is under investigation for the reduction of submental ('under-the-chin') fat.

4 Feb 2011

New report identifies top research priorities related to Female Pelvic Medicine, Reconstructive Surgery

A set of consensus recommendations identifying top research priorities related to female pelvic floor disorders is presented in the January/February issue of Female Pelvic Medicine & Reconstructive Surgery, official journal of The American Urogynecologic Society.

4 Feb 2011

U.S. Patent Office issues Notice of Allowance to Antigen Express AE37 cancer vaccine

Generex Biotechnology Corporation, together with its wholly-owned immunotherapeutic vaccines subsidiary, Antigen Express, announced today that Antigen Express has received a Notice of Allowance from the United States Patent Office relating to an application making augmentative pharmaceutical composition claims for the Antigen Express AE37 immunotherapeutic cancer vaccine.

4 Feb 2011

MicroCHIPS commences first hPTH clinical study in women with osteoporosis

MicroCHIPS, a developer of innovative drug delivery systems, is initiating the first clinical study to demonstrate precisely controlled delivery of a peptide from a multi-reservoir, programmable, implant system.

4 Feb 2011

More careful regulation of FDA's Humanitarian Device Exemption in psychiatric patients needed

Warning that patients could be at risk, an interdisciplinary group of multinational investigators is calling on the U.S. Congress and federal regulators to tighten a law that permits use of brain devices to treat rare neuropsychiatric disorders without supporting clinical trials or stringent patient oversight.

4 Feb 2011

Alimera reports 36-month results from ILUVIEN Phase 3 FAME study for DME

Alimera Sciences, Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today reported results through month 36 of the completed FAME™ Study.

4 Feb 2011

Positive top-line results from ILUVIEN Phase 3 trial in patients with DME

pSivida Corp., a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, including the investigational drug ILUVIEN for the treatment of Diabetic Macular Edema, today announced month 36, top-line readout results for the FAME Study prepared by its licensee, Alimera Sciences.

4 Feb 2011

Invacare 2010 adjusted earnings per share increase 16% to $1.84

Invacare Corporation today announced its financial results for the quarter and year ended December 31, 2010 and provided guidance for 2011.

3 Feb 2011

New England Journal publishes fidaxomicin Phase 3 trial results against CDI

Optimer Pharmaceuticals, announced The New England Journal of Medicine has published results from the North American Phase 3 trial evaluating the safety and efficacy of the Company's novel antibiotic fidaxomicin as a treatment for patients with Clostridium difficile infection.

3 Feb 2011

Inspiration presents IB1001 PK data for treatment of hemophilia B

Inspiration Biopharmaceuticals, today presented pharmacokinetic data on its lead product, IB1001, a recombinant factor IX for the treatment and prevention of bleeding in individuals with hemophilia B.

3 Feb 2011

Losartan improves effectiveness of nanotherapeutics against cancer

Low doses of an inexpensive, FDA-approved hypertension medication may improve the results of nanotherapeutic approaches to cancer treatment. In a report in the early edition of Proceedings of the National Academy of Sciences, Massachusetts General Hospital (MGH) investigators describe experiments showing that the generic drug losartan, by modifying the network of collagen fibers that characterizes most solid tumors, improved the effectiveness of two nanotherapeutics against several types of cancer.

3 Feb 2011

Efficacy News and Research

Critical care journal editors release joint statement affirming commitment to ethical conduct of research

Radical regulatory reform for life science industries needs to be a priority: Researchers

Ameritox makes significant strides to advance its industry leadership position

Stiefel introduces BPO Acne Creamy Washes for OTC use in the U.S.

Phase II results of VELCADE in patients with aggressive lymphoma published in Journal of Clinical Oncology

Amgen, Pfizer present Enbrel new trial results against psoriasis at 69th AAD meeting in New Orleans, LA

Microsulis' Microwave Endometrial Ablation platform sold to Hologic

Anacor initiates dosing in AN2728 Phase 2b trial for psoriasis

EntreMed announces publication of ENMD-2076 Phase 1 results against solid tumors in AACR journal

Positive results from KYTHERA's ATX-101 Phase IIb study for reduction of submental fat

New report identifies top research priorities related to Female Pelvic Medicine, Reconstructive Surgery

U.S. Patent Office issues Notice of Allowance to Antigen Express AE37 cancer vaccine

MicroCHIPS commences first hPTH clinical study in women with osteoporosis

More careful regulation of FDA's Humanitarian Device Exemption in psychiatric patients needed

Alimera reports 36-month results from ILUVIEN Phase 3 FAME study for DME

Positive top-line results from ILUVIEN Phase 3 trial in patients with DME

Invacare 2010 adjusted earnings per share increase 16% to $1.84

New England Journal publishes fidaxomicin Phase 3 trial results against CDI

Inspiration presents IB1001 PK data for treatment of hemophilia B

Losartan improves effectiveness of nanotherapeutics against cancer

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News